On March 8, 2022 PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, reported that the Company will present the updated data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at AACR (Free AACR Whitepaper) (American Association for Cancer Research) 2022 (Press release, PharmAbcine, MAR 8, 2022, View Source [SID1234609728]). The event will take place both onsite (New Orleans, Louisiana) and online over April 8-13, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME
Session category/title: Preclinical/Immunotherapy
Presentation Type: Online (E-poster)
Date: April 8, 2022
PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody in the development to treat various tumor types. VISTA is an immune checkpoint receptor that is mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells). It is known to play a pivotal role in maintaining the immunosuppressive environment around the tumor cells. Due to this unique mode of action, PMC-309 can provide a promising immunotherapeutic strategy and help address unmet medical needs.
"We are delighted to share the newly updated data of PMC-309 at this important annual event," said Dr. Jin-San Yoo, CEO of PharmAbcine. "Last year at both AACR (Free AACR Whitepaper) 2021 and KSMO (Korean Society of Medical Oncology) 2021, the Company presented PMC-309’s nonclinical data as of early-2021. The presentations highlighted that PMC-309 inhibits VISTA pathways on immunosuppressive cells, such as MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells) which resulted in T cell proliferation in in vitro settings and encouraging anti-tumor effects in in vivo studies. This year’s presentation will include PMC-309’s effect on monocyte activation, which is one of key immune-supportive factors. The Company is preparing an IND submission for a global clinical trial in 2022."
The abstract of the presentation is currently available on the AACR (Free AACR Whitepaper) website, and the e-poster will be accessible during the poster session at 1:00 p.m. ET on April 8 and be available for viewing through July 13.